IRVINE, CA -- (Marketwire) -- 06/18/12 -- BIOLASE, Inc. (NASDAQ: BIOL), the World's leading dental laser manufacturer and distributor, announced today that its Waterlase iPlus all-tissue dental laser system has won the Medical Devices category for the TechAmerica Orange County High-Tech Innovation Awards and was also the Bronze Winner in the dental instruments, equipment and supplies category of the 2012 Medical Design Excellence Awards® (MDEA) competition, the premier awards program for the MedTech industry.
The Waterlase iPlus, with its biological approach and Intuitive Power Control, has truly revolutionized surgery in dentistry and medicine. The iPlus not only addresses the key functional needs for the next generation of laser dentists, but it also delivers exceptional power and cutting speed with unparalleled control and versatility for all laser dentist users, from the beginner to the expert. Performing most types of procedures with the new Waterlase iPlus provides minimal to no pain or discomfort, minimizes the need for local anesthetic in most restorative cases, eliminates the risk of bacterial and viral cross-contamination associated with conventional drills and burs, and results in preserving the tissue biologically intact, and without causing the damaging micro-fractures of the tooth structure and avoiding the necrosis caused by heat and abrasion.
Federico Pignatelli, Chairman and CEO, said, "We are very pleased that our flagship product, the Waterlase iPlus, has been recognized by TechAmerica and the MDEA for its innovative design and technological capabilities. The Waterlase iPlus incorporates our patented Waterlase technology, which uses laser energy to create an expansion and vaporization of the water molecules within tissue causing a biological ablation with far less trauma than any traditional surgical device. It is the most advanced laser on the market and is a perfect example of how our engineering and marketing teams continue to lead the dental technology community in advancing laser technology to improve clinical results and provide a positive return-on-investment in dental practices."
About BIOLASE, Inc.
BIOLASE, Inc., the World's leading Dental Laser Company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate approximately 285 patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 19,600 lasers among 16,000 customers. Other products under development address ophthalmology and other medical and consumer markets.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by BIOLASE management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and BIOLASE undertakes no obligation to update such statements.